- Home
- NIE vs PHAR Comparison
NIE vs PHAR Comparison
Compare NIE & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- PHAR
- Stock Information
- Founded
- NIE 2007
- PHAR 1988
- Country
- NIE United States
- PHAR Netherlands
- Employees
- NIE N/A
- PHAR N/A
- Industry
- NIE Investment Managers
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NIE Finance
- PHAR Health Care
- Exchange
- NIE Nasdaq
- PHAR Nasdaq
- Market Cap
- NIE 697.4M
- PHAR 718.1M
- IPO Year
- NIE N/A
- PHAR N/A
- Fundamental
- Price
- NIE $22.80
- PHAR $10.45
- Analyst Decision
- NIE
- PHAR Strong Buy
- Analyst Count
- NIE 0
- PHAR 3
- Target Price
- NIE N/A
- PHAR $30.00
- AVG Volume (30 Days)
- NIE 70.5K
- PHAR 2.6K
- Earning Date
- NIE 01-01-0001
- PHAR 07-31-2025
- Dividend Yield
- NIE 9.04%
- PHAR N/A
- EPS Growth
- NIE N/A
- PHAR N/A
- EPS
- NIE N/A
- PHAR N/A
- Revenue
- NIE N/A
- PHAR $320,708,000.00
- Revenue This Year
- NIE N/A
- PHAR $13.31
- Revenue Next Year
- NIE N/A
- PHAR $7.68
- P/E Ratio
- NIE N/A
- PHAR N/A
- Revenue Growth
- NIE N/A
- PHAR 24.13
- 52 Week Low
- NIE $18.61
- PHAR $6.65
- 52 Week High
- NIE $22.47
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- NIE 44.96
- PHAR 47.51
- Support Level
- NIE $22.74
- PHAR $10.41
- Resistance Level
- NIE $23.20
- PHAR $11.50
- Average True Range (ATR)
- NIE 0.29
- PHAR 0.32
- MACD
- NIE -0.11
- PHAR -0.17
- Stochastic Oscillator
- NIE 5.69
- PHAR 2.26
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments such as aerospace and defense, banks, IT services, software, and others.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.